881 Antisynthetase syndrome and dermatomyositis immunophenotyping

Antisynthetase syndrome

The Antisynthetase Syndrome

The antisynthetase syndrome (ASS) was first described by Marguerie and coworkers in 1990 as a triad of polymyositis, diffuse interstitial lung disease (ILD) and serum autoantibodies to aminoacyl transfer RNA synthetases (anti-ARS) (1). Later, cohort studies have indicated that 20-25 % of patients diagnosed with polymyositis (PM) or dermatomyositis (DM) have antiARS antibodies (2-4). In most cas...

Drug-induced antisynthetase syndrome.

We present a case of antisynthetase syndrome whose predominant feature was fibrosing alveolitis and which may have been drug-induced. This responded well to steroids and cyclophosphamide.

Anti-Jo-1 antisynthetase syndrome.

OBJECTIVE Given a lack of population-based studies, we report an epidemiological-clinic study of anti-Jo-1 antisynthetase syndrome (ASS). PATIENTS AND METHODS To study a retrospective cohort of a single-center from 1980 to 2010. Clinical-laboratory and demographic data were obtained from medical files. All patients fulfilled the Bohan and Peter criteria (1975) and presented anti-Jo-1, articul...

New Insights into Antisynthetase Syndrome.

Antisynthetase syndrome (ASS) is a rare chronic autoimmune disorder (2-3 times more common in women than in men), associated with interstitial lung disease (the most important feature), dermatomyositis (DM), and polymyositis (PM). The cause of ASS is unknown. Recent developments in immunology have improved our knowledge and it is now possible to classify ASS according to the presence of myositi...